GERN

About GERN

Geron Corporation is a late-stage biopharmaceutical company. The Company is focused on the development and commercialization of imetelstat, a therapeutic for hematologic malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13mer oligonucleotide that the Company designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Its lead indication for imetelstat is in low or intermediate-1 risk myelodysplastic syndromes (MDS). It is also engaged in the development of two indications, such as the treatment of adult patients with transfusion-dependent anemia due to lower risk MDS, and the treatment of adult patients with Intermediate-2 or High-Risk MF whose disease has relapsed after or is refractory to janus associate kinase inhibitor (JAK) inhibitor treatment.